{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:40:06Z","timestamp":1749908406667,"version":"3.41.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13189-8","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T12:41:54Z","timestamp":1749040914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7414-3533","authenticated-orcid":false,"given":"Hui","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"3","key":"13189_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","volume":"8","author":"H Lassmann","year":"2018","unstructured":"Lassmann H (2018) Multiple sclerosis pathology. Cold Spring Harb Perspect Med 8(3):a028936. https:\/\/doi.org\/10.1101\/cshperspect.a028936","journal-title":"Cold Spring Harb Perspect Med"},{"key":"13189_CR2","unstructured":"\u201cMultiple sclerosis | nature reviews disease primers.\u201d Accessed: Feb. 13, 2025. [Online]. Available: https:\/\/www.nature.com\/articles\/s41572-018-0041-4"},{"issue":"9","key":"13189_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","volume":"8","author":"S Klineova","year":"2018","unstructured":"Klineova S, Lublin FD (2018) Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med 8(9):a028928. https:\/\/doi.org\/10.1101\/cshperspect.a028928","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"13189_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1177\/1352458516686847","volume":"24","author":"MP Amato","year":"2018","unstructured":"Amato MP et al (2018) Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult Scler J 24(5):590\u2013603. https:\/\/doi.org\/10.1177\/1352458516686847","journal-title":"Mult Scler J"},{"issue":"5","key":"13189_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2217\/nmt.15.33","volume":"5","author":"RM Lucas","year":"2015","unstructured":"Lucas RM, Byrne SN, Correale J, Ilschner S, Hart PH (2015) Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegener Dis Manag 5(5):413\u2013424. https:\/\/doi.org\/10.2217\/nmt.15.33","journal-title":"Neurodegener Dis Manag"},{"key":"13189_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010012","author":"G Jalkh","year":"2020","unstructured":"Jalkh G, Abi Nahed R, Macaron G, Rensel M (2020) Safety of newer disease modifying therapies in multiple sclerosis. Vaccines. https:\/\/doi.org\/10.3390\/vaccines9010012","journal-title":"Vaccines"},{"issue":"9","key":"13189_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/acn3.50862","volume":"6","author":"E Waubant","year":"2019","unstructured":"Waubant E et al (2019) Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol 6(9):1905\u20131922. https:\/\/doi.org\/10.1002\/acn3.50862","journal-title":"Ann Clin Transl Neurol"},{"issue":"17","key":"13189_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A et al (2018) Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis. Neurology 90(17):789\u2013800. https:\/\/doi.org\/10.1212\/WNL.0000000000005345","journal-title":"Neurology"},{"issue":"1","key":"13189_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","volume":"328","author":"A Groves","year":"2013","unstructured":"Groves A, Kihara Y, Chun J (2013) Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328(1):9\u201318. https:\/\/doi.org\/10.1016\/j.jns.2013.02.011","journal-title":"J Neurol Sci"},{"issue":"3","key":"13189_CR10","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s13311-021-01048-z","volume":"18","author":"ES Frisch","year":"2021","unstructured":"Frisch ES, Pretzsch R, Weber MS (2021) A milestone in multiple sclerosis therapy: monoclonal antibodies against CD20\u2014yet progress continues. Neurotherapeutics 18(3):1602\u20131622. https:\/\/doi.org\/10.1007\/s13311-021-01048-z","journal-title":"Neurotherapeutics"},{"issue":"4","key":"13189_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","volume":"14","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Cree BAC, Hauser SL (2017) Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 14(4):835\u2013841. https:\/\/doi.org\/10.1007\/s13311-017-0557-4","journal-title":"Neurotherapeutics"},{"issue":"1","key":"13189_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1352458520949158","volume":"28","author":"ALM Jordan","year":"2022","unstructured":"Jordan ALM, Yang J, Fisher CJ, Racke MK, Mao-Draayer Y (2022) Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler 28(1):7\u201315. https:\/\/doi.org\/10.1177\/1352458520949158","journal-title":"Mult Scler"},{"issue":"3","key":"13189_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","volume":"29","author":"EM Williamson","year":"2015","unstructured":"Williamson EM,  Berger JR (2015) Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs 29(3):229\u2013244. https:\/\/doi.org\/10.1007\/s40263-015-0226-2","journal-title":"CNS Drugs"},{"issue":"4","key":"13189_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13311-017-0570-7","volume":"14","author":"EML Williamson","year":"2017","unstructured":"Williamson EML, Berger JR (2017) Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics 14(4):961\u2013973. https:\/\/doi.org\/10.1007\/s13311-017-0570-7","journal-title":"Neurotherapeutics"},{"issue":"6","key":"13189_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M et al (2024) The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf 47(6):585\u2013599. https:\/\/doi.org\/10.1007\/s40264-024-01423-7","journal-title":"Drug Saf"},{"issue":"17","key":"13189_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant  A et al (2018) Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology 90(17):777\u2013788. https:\/\/doi.org\/10.1212\/WNL.0000000000005347","journal-title":"Neurology"},{"issue":"2","key":"13189_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X et al (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 25(2):215\u2013237. https:\/\/doi.org\/10.1111\/ene.13536","journal-title":"Eur J Neurol"},{"issue":"2","key":"13189_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20(2):109\u2013117. https:\/\/doi.org\/10.2165\/00002018-199920020-00002","journal-title":"Drug Saf"},{"key":"13189_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100315","author":"NE Omar","year":"2021","unstructured":"Omar NE, Soliman AIF, Eshra M, Saeed T, Hamad A, Abou-Ali A (2021) Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: n analysis of the FDA adverse event reporting system (FAERS). ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100315","journal-title":"ESMO Open"},{"key":"13189_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4672","author":"C Fukazawa","year":"2018","unstructured":"Fukazawa C et al (2018) Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf. https:\/\/doi.org\/10.1002\/pds.4672","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"13189_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidem Dr S 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidem Dr S"},{"issue":"1","key":"13189_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"13189_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A et al (1998) A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"13189_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/j.1365-2125.2011.04087.x","volume":"72","author":"A de Boer","year":"2011","unstructured":"de Boer A (2011) When to publish measures of disproportionality derived from spontaneous reporting databases? Br J Clin Pharmacol 72(6):909\u2013911. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04087.x","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"13189_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72(6):905\u2013908. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037.x","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"13189_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, Neill RTO (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA??s spontaneous reports database. Drug Saf 25(6):381\u2013392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001","journal-title":"Drug Saf"},{"key":"13189_CR27","doi-asserted-by":"publisher","first-page":"1425617","DOI":"10.3389\/fphar.2024.1425617","volume":"15","author":"K Mao","year":"2024","unstructured":"Mao K, Chen P, Sun H, Zhong S, Zheng H, Xu L (2024) Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS). Front Pharmacol 15:1425617. https:\/\/doi.org\/10.3389\/fphar.2024.1425617","journal-title":"Front Pharmacol"},{"issue":"1","key":"13189_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s10194-024-01858-4","volume":"25","author":"J-L Hu","year":"2024","unstructured":"Hu J-L, Wu J-Y, Xu S, Qian S-Y, Jiang C, Zheng G-Q (2024) Post-marketing safety concerns with rimegepant based on a pharmacovigilance study. J Headache Pain 25(1):169. https:\/\/doi.org\/10.1186\/s10194-024-01858-4","journal-title":"J Headache Pain"},{"issue":"1","key":"13189_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","volume":"25","author":"W-H Liu","year":"2024","unstructured":"Liu W-H et al (2024) Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. food and drug administration (FDA) adverse event reporting system (FAERS) database. J Headache Pain 25(1):206. https:\/\/doi.org\/10.1186\/s10194-024-01913-0","journal-title":"J Headache Pain"},{"issue":"2","key":"13189_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung H-P (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33(2):91\u2013101. https:\/\/doi.org\/10.1097\/WNF.0b013e3181cbf825","journal-title":"Clin Neuropharmacol"},{"issue":"17","key":"13189_CR31","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1073\/pnas.1618659114","volume":"114","author":"K Yanagida","year":"2017","unstructured":"Yanagida K et al (2017) Size-selective opening of the blood\u2013brain barrier by targeting endothelial sphingosine 1\u2013phosphate receptor 1. Proc Natl Acad Sci USA 114(17):4531\u20134536. https:\/\/doi.org\/10.1073\/pnas.1618659114","journal-title":"Proc Natl Acad Sci USA"},{"key":"13189_CR32","doi-asserted-by":"publisher","unstructured":"Thompson J, Yang Y, Duval K, Griego M, Chen H, SantaCruz K, Deng H, Perez C, Maez S, Hobson S, Li T, Akter H, Torbey M, Yang Y (2024) Progressive disruption of sphingosine-1-phosphate receptor 1 correlates with blood-brain barrier leakage in a rat model of chronic hypoxic hypoperfusion. Aging Dis 16(2):1099\u20131119. https:\/\/doi.org\/10.14336\/AD.2024.0098","DOI":"10.14336\/AD.2024.0098"},{"issue":"4","key":"13189_CR33","doi-asserted-by":"publisher","first-page":"ENEURO.40-21.20","DOI":"10.1523\/ENEURO.0040-21.2021","volume":"8","author":"D Jonnalagadda","year":"2021","unstructured":"Jonnalagadda D, Kihara Y, Rivera R, Chun J (2021) S1P2 -G\u03b112 signaling controls astrocytic glutamate uptake and mitochondrial oxygen consumption. Eneuro 8(4):p ENEURO.40-21.2021. https:\/\/doi.org\/10.1523\/ENEURO.0040-21.2021","journal-title":"Eneuro"},{"issue":"8","key":"13189_CR34","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/cdd.2011.7","volume":"18","author":"N Hagen","year":"2011","unstructured":"Hagen N, Hans M, Hartmann D, Swandulla D, Van Echten-Deckert G (2011) Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism. Cell Death Differ 18(8):1356\u20131365. https:\/\/doi.org\/10.1038\/cdd.2011.7","journal-title":"Cell Death Differ"},{"key":"13189_CR35","doi-asserted-by":"publisher","first-page":"549842","DOI":"10.3389\/fimmu.2020.549842","volume":"11","author":"K Khoy","year":"2020","unstructured":"Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B (2020) Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring. Front Immunol 11:549842. https:\/\/doi.org\/10.3389\/fimmu.2020.549842","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"13189_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jneuroim.2007.11.007","volume":"194","author":"RLP Lindberg","year":"2008","unstructured":"Lindberg RLP, Achtnichts L, Hoffmann F, Kuhle J, Kappos L (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 194(1\u20132):153\u2013164. https:\/\/doi.org\/10.1016\/j.jneuroim.2007.11.007","journal-title":"J Neuroimmunol"},{"issue":"1","key":"13189_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1756285615615257","volume":"9","author":"F Sellebjerg","year":"2016","unstructured":"Sellebjerg F, Cadavid D, Steiner D, Villar LM, Reynolds R, Mikol D (2016) Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord 9(1):31\u201343. https:\/\/doi.org\/10.1177\/1756285615615257","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"13189_CR38","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","volume":"64","author":"GPA Rice","year":"2005","unstructured":"Rice GPA, Hartung H-P, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64(8):1336\u20131342. https:\/\/doi.org\/10.1212\/01.WNL.0000158329.30470.D0","journal-title":"Neurology"},{"issue":"9","key":"13189_CR39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397","journal-title":"N Engl J Med"},{"issue":"2","key":"13189_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2492\/inflammregen.31.167","volume":"31","author":"K Chiba","year":"2011","unstructured":"Chiba K, Kataoka H, Seki N, Maeda Y, Sugahara K (2011) Fingolimod (FTY720), the sphingosine 1-phosphate receptor modulator, as a new therapeutic drug in multiple sclerosis. Inflamm Regen 31(2):167\u2013174. https:\/\/doi.org\/10.2492\/inflammregen.31.167","journal-title":"Inflamm Regen"},{"issue":"6","key":"13189_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.4155\/fmc.12.25","volume":"4","author":"K Chiba","year":"2012","unstructured":"Chiba K, Adachi K (2012) Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis. Future Med Chem 4(6):771\u2013781. https:\/\/doi.org\/10.4155\/fmc.12.25","journal-title":"Future Med Chem"},{"issue":"9","key":"13189_CR42","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00415-014-7395-7","volume":"261","author":"AE Miller","year":"2014","unstructured":"Miller AE et al (2014) Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol 261(9):1781\u20131788. https:\/\/doi.org\/10.1007\/s00415-014-7395-7","journal-title":"J Neurol"},{"issue":"6","key":"13189_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","volume":"74","author":"A Bar-Or","year":"2014","unstructured":"Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74(6):659\u2013674. https:\/\/doi.org\/10.1007\/s40265-014-0212-x","journal-title":"Drugs"},{"issue":"1","key":"13189_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells8010012","volume":"8","author":"S Gingele","year":"2018","unstructured":"Gingele S et al (2018) Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients. Cells 8(1):12. https:\/\/doi.org\/10.3390\/cells8010012","journal-title":"Cells"},{"issue":"3","key":"13189_CR45","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s11481-020-09931-w","volume":"16","author":"A Carnasciali","year":"2021","unstructured":"Carnasciali A et al (2021) T cell delivery of nanoparticles-bound anti-CD20 monoclonal antibody: successful B cell depletion in the spinal cord during experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 16(2):376\u2013389. https:\/\/doi.org\/10.1007\/s11481-020-09931-w","journal-title":"J Neuroimmune Pharmacol"},{"issue":"12","key":"13189_CR46","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.4049\/jimmunol.1301926","volume":"191","author":"X Zhang","year":"2013","unstructured":"Zhang X et al (2013) Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing\u2013remitting multiple sclerosis. J Immunol 191(12):5867\u20135874. https:\/\/doi.org\/10.4049\/jimmunol.1301926","journal-title":"J Immunol"},{"key":"13189_CR47","doi-asserted-by":"publisher","first-page":"1249201","DOI":"10.3389\/fimmu.2023.1249201","volume":"14","author":"MR Von Essen","year":"2023","unstructured":"Von Essen MR, Chow HH, Holm Hansen R, Buhelt S, Sellebjerg F (2023) Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control. Front Immunol 14:1249201. https:\/\/doi.org\/10.3389\/fimmu.2023.1249201","journal-title":"Front Immunol"},{"issue":"7","key":"13189_CR48","doi-asserted-by":"publisher","first-page":"16414","DOI":"10.3390\/ijms160716414","volume":"16","author":"T Ruck","year":"2015","unstructured":"Ruck T, Bittner S, Wiendl H, Meuth S (2015) Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 16(7):16414\u201316439. https:\/\/doi.org\/10.3390\/ijms160716414","journal-title":"Int J Mol Sci"},{"issue":"10","key":"13189_CR49","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a032029","volume":"8","author":"S Katsavos","year":"2018","unstructured":"Katsavos S, Coles A (2018) Alemtuzumab as treatment for multiple sclerosis. Cold Spring Harb Perspect Med 8(10):a032029. https:\/\/doi.org\/10.1101\/cshperspect.a032029","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"13189_CR50","doi-asserted-by":"publisher","first-page":"879","DOI":"10.32598\/bcn.2021.2848.2","volume":"14","author":"M Salehbayat","year":"2023","unstructured":"Salehbayat M, Abolfazli R, Mohebbi N, Savar SM, Shalviri G, Gholami K (2023) Adverse drug reactions of multiple sclerosis disease-modifying drugs. Basic Clin Neurosci 14(6):879\u2013883. https:\/\/doi.org\/10.32598\/bcn.2021.2848.2","journal-title":"Basic Clin Neurosci"},{"key":"13189_CR51","doi-asserted-by":"publisher","first-page":"1376494","DOI":"10.3389\/fphar.2024.1376494","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Yan Y, Liu S, Wang Z, Feng X (2024) Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: An analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol 15:1376494. https:\/\/doi.org\/10.3389\/fphar.2024.1376494","journal-title":"Front Pharmacol"},{"issue":"7","key":"13189_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s000110050332","volume":"47","author":"L Jansson","year":"1998","unstructured":"Jansson L, Holmdahl R (1998) Estrogen-mediated immunosuppression in autoimmune diseases. Inflamm Res 47(7):290\u2013301. https:\/\/doi.org\/10.1007\/s000110050332","journal-title":"Inflamm Res"},{"issue":"40","key":"13189_CR53","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/eurheartj\/ehv161","volume":"36","author":"GMC Rosano","year":"2015","unstructured":"Rosano  GMC et al (2015) Gender differences in the effect of cardiovascular drugs: a position document of the working group on pharmacology and drug therapy of the ESC: figure 1. Eur Heart J 36(40):2677\u20132680. https:\/\/doi.org\/10.1093\/eurheartj\/ehv161","journal-title":"Eur Heart J"},{"issue":"5","key":"13189_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","volume":"41","author":"B Meibohm","year":"2002","unstructured":"Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41(5):329\u2013342. https:\/\/doi.org\/10.2165\/00003088-200241050-00002","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"13189_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00003088-200342020-00001","volume":"42","author":"JB Schwartz","year":"2003","unstructured":"Schwartz JB (2003) The influence of sex on pharmacokinetic. Clin Pharmacokinet 42(2):107\u2013121. https:\/\/doi.org\/10.2165\/00003088-200342020-00001","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"13189_CR56","first-page":"150","volume":"60","author":"K Kroenke","year":"1998","unstructured":"Kroenke K, Spitzer RL (1998) Gender differences in the reporting of physical and somatoform symptoms. Biopsychosoc Sci Med 60(2):150","journal-title":"Biopsychosoc Sci Med"},{"key":"13189_CR57","doi-asserted-by":"publisher","first-page":"175628641987832","DOI":"10.1177\/1756286419878324","volume":"12","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L (2019) Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord 12:1756286419878324. https:\/\/doi.org\/10.1177\/1756286419878324","journal-title":"Ther Adv Neurol Disord"},{"issue":"9856","key":"13189_CR58","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829\u20131839. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"13189_CR59","doi-asserted-by":"publisher","first-page":"103350","DOI":"10.1016\/j.msard.2021.103350","volume":"57","author":"M Salvetti","year":"2022","unstructured":"Salvetti M et al (2022) Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the plegridy observational program. Mult Scler Relat Disord 57:103350. https:\/\/doi.org\/10.1016\/j.msard.2021.103350","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"13189_CR60","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1177\/1352458514557986","volume":"21","author":"BC Kieseier","year":"2015","unstructured":"Kieseier BC et al (2015) Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 21(8):1025\u20131035. https:\/\/doi.org\/10.1177\/1352458514557986","journal-title":"Mult Scler"},{"issue":"7","key":"13189_CR61","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","volume":"16","author":"YM Alatawi","year":"2017","unstructured":"Alatawi YM, Hansen RA (2017) Empirical estimation of under-reporting in the U.S. food and drug administration adverse event reporting system (FAERS). Expert Opin Drug Saf  16(7):761\u2013767. https:\/\/doi.org\/10.1080\/14740338.2017.1323867","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13189-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13189-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13189-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:24:46Z","timestamp":1749907486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13189-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13189"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13189-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study does not involve human or animal subjects, and therefore, ethical approval was not required. The data used are secondary data from the publicly available FDA Adverse Event Reporting System (FAERS), which is anonymized and does not include personally identifiable information. As this study utilizes publicly available, anonymized data from the FDA Adverse Event Reporting System (FAERS), patient consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"445"}}